OBJECTIVES: Expert consensus recommends calendar based in-office follow-up (FU) for pacemakers (PM) twice annually, for internal cardioverter defibrillator (ICD) or cardiac resynchronisation therapy devices (CRT) four times a year. To estimate the societal costs of these FUs in Germany and the UK (UK). To estimate potential cost savings from switching from conventional to a BIOTRONIK Home Monitoring FU (remote monitoring) regimen. METHODS: Prevalence-based estimates on the number of in-office FU visits were combined with data on private and ambulance transport and hospital services, with costs projected until 2015. RESULTS: Annual cost of routine FU in Germany are estimated to climb from EURO 106 mio (2010) to 142 mio (2015). For the UK, costs are forecast to rapidly increase from EURO 31 mio (2010) to 49 mio (2015). In Germany, patients bear the majority of the costs (61%), followed by hospital service costs (31%). In the UK, the situation is reversed with hospital costs contributing the most (84%), followed by patient travel costs (12%). The remainder is health insurance costs for ambulance transport. If 50% of all patients would attend one in-office visit annually and have their other FUs performed with Home Monitoring, annual cost savings in 2015 could reach EURO 43.9 mio in Germany, and EURO 14.7 mio in the UK. CONCLUSIONS: For the first time, costs of FU for PM and ICD/CRT in Germany and the UK are presented. As modern devices are capable to self-declare parameter deviations indicative for malfunctions or worsening disease, remote monitoring can help eliminating unnecessary visits. The presented savings are expected to be heavily underestimated due to not considering the impact of earlier event detection and improved disease outcomes. Savings could be invested in remote monitoring technologies, and freed medical specialist capacities be re-directed to CIED patients in real need of FU visits.
OBJECTIVES:
In the US the monitoring of patients with Chronic Myeloid Leukaemia (CML) presents extensive intra-and inter-lab variability, thus a standardised, automated test should allow for improvement in patient management and health outcomes. The aim of the study was to estimate the budget impact and improved testing accuracy associated with a the use of a standardised, automated BCR-ABL monitoring test (SBAT) when compared to laboratory developed tests (LDTs) for newly diagnosed CML patients over a 5-year period in the US. METHODS: Epidemiology data regarding the incidence of Philadelphia positive (Phϩ) CML patients who would be treated with a tyrosine kinase inhibitor (TKI) were combined with workflow cost and accuracy (sensitivity and specificity) data associated with the sequential testing and monitoring of newly diagnosed CML patients. A survey of US laboratories was conducted to determine the labour and materials costs associated with the SBAT versus LDTs. A testing algorithm based on NCCN guidelines was used to capture a number of different tests including testing for major molecular response (SBAT versus LDTs), complete cytogenetic response (routine and FISHfluorescence in situ hybridisation), and mutation analysis. RESULTS: Results indicate that the SBAT is both less resource-and labour-intensive, and can be carried out at a cost that is lower than when an LDT is used. In addition, overall test accuracy increases when the SBAT is used instead of an LDT. For example, for every 100 patients who follow BCR-ABL monitoring according to NCCN guidelines, savings of approximately $386,180 and approximately 327 more accurate test results could be achieved over 5 years. CONCLUSIONS: The benefits from a SBAT when compared to LDTs are not only from the reduction of intra-and inter-lab variability (increased accuracy) but also in economic terms due to lower overall costs. Therefore, a SBAT represents a cost-saving alternative versus LDTs.
PMD17 NOBLE METAL ALLOY-COATED URETHRAL CATHETER: A BUDGET IMPACT ANALYSIS IN THE VENETO REGION OF ITALY
Fantelli V 1 , Van de Vooren K 2 , Curto A 2 , Filippi C 1 , Bassotto F 1 , Garattini L 2 , Scroccaro G 1 1 UVEF -Drug effectiveness evaluation unit of the Regional Coordination for pharmaceutical agents -Department of Pharmacy, Verona, Italy, 2 CESAV -Center for Health Economics "Angelo & Angela Valenti ", Ranica, Bergamo, Italy OBJECTIVES: The aim of this paper is to illustrate a methodology to develop a BIA, assisting the decision maker in answering the question on financial sustainability. METHODS: The analysis compared the new coated urethral catheter (alternative A) to the long-term catheter currently in use in the region (alternative B). The study, built on efficacy data including "asymptomatic bacteriuria" solely, adopted the perspective of the Regional Health Service. A survey was conducted in seven local health authorities (LHAs) within the Region to obtain consumption data and the average price of respectively the new and currently used long-term catheters. The estimate of regional consumption of alternative B was obtained by projecting the consumption of 7 LHAs on the basis of the percentage of total inpatient admissions. The analysis included technology costs and the costs of additional hospitalization days due to Catheter Associated Urinary Tract Infections (CAUTI). Sensitivity analyses were conducted to test the robustness of the results in the "base case".
RESULTS:
In 2010 approximately 25.000 long-term catheters with an average price of 3.57 € were consumed. The regional estimate of annual consumption is about 221.560 catheters, with a total cost of € 791.000 per year. In the case of adopting alternative A, the base case analysis estimated savings of around € 200.000 per year. The one-way sensitivity analysis confirmed the extreme variability of the final result as a function of the confidence interval of the clinical efficacy. A more favorable result for the new catheter can be reached using a "two-way" analysis, combining a higher CAUTI incidence and a higher level of effectiveness (€2.045.866).
CONCLUSIONS:
The results are strongly influenced by the effectiveness of the new technology: a slight clinical benefit is enough to make the new catheter economically viable. OBJECTIVES: Open spine surgery (OS) is associated with significant muscle trauma leading to delayed recovery, prolonged pain, and significant medical resource utilization. Minimal Access Spinal Technologies (MAST™) aim at minimizing muscle trauma, reduce blood loss, decrease postoperative pain, reduce length of stay in hospital (LoS), and expedite return to normal activities for the patient. The objective of this study is to determine and compare the resource consumption associated with open vs. minimal invasive surgery in patients with degenerative spinal disorder. METHODS: This activity-based cost-analysis was conducted in two Italian hospitals where patient flow and resource utilization were mapped and segmented through interviews with medical staff. Unit costs were retrieved from public sources and hospital data for the following categories 1) staff time; 2) tests; 3) drugs/consumables; 4) operating room (OR); 5) spinal implants/instrumentation; and 6) general costs. Costs were compared between pathways (open vs. MAST™) and for each phase (pre-hospitalization, hospitalization, surgery, post-surgery and follow-up. RESULTS: Both surgery and post-surgery were the most resource intense episodes: on average post-surgery accounted for 14% of the total costs in MAST™, and 24% in OS. MAST™ was associated with less overall resource use in both hospitals, mainly driven by shorter LoS post surgery (2 vs. 4 days), less blood loss and less demanding wound care. Total hospitalization costs were €6970-8310 for MAST™ and €8021-8760 for OS. CONCLUSIONS: The study confirms published evidence on the shorter LoS with MAST™ and the economic benefits of a less invasive procedure. Despite initial higher investments (instrumentation, learning curve) MAST™ may be an effective and cost-saving alternative to OS. Further cost savings may be incurred due to faster return to work, not investigated in this study.
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COST-EFFECTIVENESS OF IMPLANTABLE DEFIBRILLATORS AFTER MYOCARDIAL INFARCTION BASED ON 8-YEAR FOLLOW-UP DATA (MADIT II)
Gandjour A 1 , Holler A 2 , Adarkwah CC 3 1 Pennington Biomedical Research Center/Louisiana State University, Baton Rouge, LA, USA, 2 University of Cologne, Köln, Germany, 3 Maastricht University, Maastricht, The Netherlands OBJECTIVES: About 190,000 Germans suffer a myocardial infarction (MI) each year. Of these, 25% may be eligible for an implantable cardioverter defibrillator (ICD) due to low left ventricular ejection fraction. Given the high costs of implantation, the purpose of this study was to assess the cost-effectiveness of ICDs compared to conventional therapy in patients with an ejection fraction Յ 30% after MI in Germany. METHODS: The economic evaluation was performed from the perspective of the German statutory health insurance (SHI). In order to simulate costs and effectiveness over lifetime, a Markov model was constructed with 7 health states. The model was based on 8-year follow-up data for ICD implantation after MI (MA-DIT II), which were published recently. RESULTS: The analysis shows that ICD implantation compared to conventional therapy in patients fulfilling MADIT-II criteria has a cost-effectiveness ratio of €44 736 per quality-adjusted life year gained. If every patient insured by the SHI and fulfilling the MADIT-II criteria would receive an ICD, the model suggests expenditures between €173 million and €1.7 billion per year. CONCLUSIONS: ICD therapy cannot be considered clearly cost-effective when compared to many well-accepted interventions. If policy makers decide to reimburse ICDs in the MADIT-II population, they will need to either raise premiums or abandon coverage for other currently funded medical interventions. OBJECTIVES: Deep brain stimulation (DBS) use in dystonia is associated with high energy needs and as such frequent replacement of the device. The first rechargeable DBS device (Activa ® RC) offers a guaranteed 9 years longevity. Our objective is to perform a cost analysis of Activa ® RC compared to the non rechargeable neurostimulators in dystonia patients in France. METHODS: A retrospective data collection was performed in a Neurosurgery Department (Pr. Ph. Coubes -Montpellier Public Hospital) with significant experience in DBS for dystonia. The cost analysis was based on direct medical costs, from a national insurance perspective. The evaluation concerns the device and hospitalization tariffs, the procedure cost being included in the hospitalization tariffs, in France, for the public hospitals. We compared the time to replacement with non-rechargeable devices versus rechargeable device, extrapolated over 9 years. A sensitivity analysis was performed using timeto-replacement variable. RESULTS: The cohort included 63 consecutive dystonia A247 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 -A 5 1 0
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